A single centre, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin(R)) and topical clindamycin lotion (Dalacin(R) T) in subjects with mild to moderate acne. The Journal of dermatological treatment. [J Dermatolog Treat] Journal article | | Title | A single centre, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin(R)) and topical clindamycin lotion (Dalacin(R) T) in subjects with mild to moderate acne. | | Author(s) | Chassard D, Kanis R, Namour F, Evene E, Ntssikoussalabongui B, Schmitz V | | Institution | Aster Cephac, Paris, FranceStrakan Ltd, Buckholm Mill, Galashiels, UK. | | Source | J Dermatolog Treat 2006; 17(3):154-7. | | Abstract | Zinc/clindamycin gel (Zindaclin(R) 1%) gel, is a new once-daily topical acne treatment (Strakan Ltd) containing clindamycin phosphate equivalent to 1% clindamycin and zinc acetate in a formulation, which leads to a reduced systemic absorption of clindamycin through the skin. The objective of the study was to compare the systemic absorption of clindamycin from zinc/clindamycin gel and clindamycin lotion (Dalacin(R) T topical lotion, Pharmacia Ltd) after repeated twice-daily topical administration for two periods of 5 days with an intervening gap of 2 weeks in 24 subjects with mild to moderate acne. Plasma Cmax, and AUC0-12 of clindamycin measured after single and multiple applications of zinc/clindamycin gel were between 30% and 50% lower than for clindamycin lotion. As zinc/clindamycin gel is a topical treatment for acne, the lower systemic bioavailability may be beneficial because there may be a correspondingly lower risk of systemic events in zinc/clindamycin gel-treated subjects. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 16854755 |
|
|
| |
Advertise on this site.
| | |
|
